Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01746836 · ClinicalTrials.gov registry record · Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
A Phase 2 study of Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01746836 is a Phase 2 study of Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 72-participant average among 7 other Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01746836, a Phase 2 study of Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells by blocking a protein needed for cell growth.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- DRUG Ponatinib Hydrochloride
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-01-17 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01746836
The ClinicalTrials.gov registry entry for NCT01746836 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 7 other Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (31% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT01746836 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01746836 about?
NCT01746836 is a clinical study titled "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib". This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate,...
What is the current status of trial NCT01746836?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2013-01-17. Estimated completion is 2030-12-31.
What conditions does trial NCT01746836 study?
This clinical trial studies the following conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT01746836?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Ponatinib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01746836?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01746836 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized NK Cell Therapy in CBT
RECRUITING · Phase 2
-
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
ACTIVE NOT RECRUITING · Phase 2
-
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
All registered trials for this condition
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.